Filing summary
Important identification note: The request identifies PDS Biotechnology Corp., but the supplied filing is for Edge Therapeutics, Inc. (Form 10-Q, quarter ended June 30, 2016). The summary below reflects the supplied filing and should not be attributed to PDS Biotechnology without verifying the source.
Business context and reporting period
Edge Therapeutics was a clinical-stage biotechnology company developing hospital-based treatments for acute neurological conditions. Its lead candidate, EG-1962, was being developed for aneurysmal subarachnoid hemorrhage (aSAH); the company had no approved products and had generated no revenue. The filing reports the three and six months ended June 30, 2016, compared with the corresponding 2015 periods.
Financial performance and liquidity
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $6.0 million | $3.2 million | $11.3 million | $6.1 million |
| General and administrative expense | $3.3 million | $1.8 million | $7.0 million | $3.1 million |
| Net loss | $9.4 million | $5.5 million | $18.5 million | $10.0 million |
| Net cash used in operating activities | Not stated for quarter | Not stated for quarter | $17.3 million | $10.0 million |
Gross margin and operating margin are not meaningful because the company had no product revenue. Cash and cash equivalents were $111.0 million at June 30, 2016, down $19.2 million from December 31, 2015. Total assets were $115.4 million; total liabilities were approximately $8.7 million, including $4.3 million of debt principal reported on the balance sheet. The company reported $6.8 million of current liabilities. Six-month investing cash outflow was $0.2 million, and financing cash outflow was $1.6 million.
Material changes versus prior periods
- Second-quarter operating expenses rose 87% year over year, and net loss increased by $3.9 million. For the first six months, operating expenses doubled and net loss increased by $8.6 million.
- Management attributed higher R&D expense primarily to increased external EG-1962 trial costs and additional personnel and departmental spending. Higher G&A reflected personnel, stock compensation, facilities, professional fees, and public-company costs.
- Operating cash use increased by $7.4 million year over year for the first six months. Stock-based compensation was $2.8 million for the period, versus $1.0 million in 2015.
- Cash and cash equivalents declined from $130.2 million at year-end 2015 to $111.0 million at June 30, 2016. Debt principal payments during the first half were approximately $1.1 million.
Outlook, risks, and subsequent events
- Management said June 30 cash was expected to fund operations through the anticipated 2018 full data readout of the planned EG-1962 Phase 3 pivotal trial. This was an estimate subject to clinical, regulatory, spending, and financing uncertainties.
- The Phase 3 EG-1962 program began in July 2016. The filing also described plans for a small open-label study of an alternate administration route in the second half of 2016 and an IND submission for EG-1964 in 2017.
- After quarter-end, the first patient was treated in the Phase 3 NEWTON 2 trial. This triggered a $1.0 million milestone payment to Evonik. The license also includes potential future development, regulatory, and sales milestones, and mid-single-digit royalties on certain product sales.
- On August 1, 2016, the company entered into an amended loan agreement and borrowed the available $15.0 million, less amounts outstanding under the prior facility. It could elect to draw another $5.0 million by June 15, 2017. The new facility bears interest at a stated floor of 9.15% (subject to the agreement’s formula), is secured by substantially all assets other than intellectual property, and includes customary restrictive covenants.
- Key risks include clinical-trial outcomes and timing, FDA requirements (including the possibility of an additional Phase 3 trial or design changes), regulatory approval, competition, manufacturing and vendor performance, intellectual-property protection, and the need for future capital. The filing reported no material litigation, no material changes to previously disclosed risk factors, and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Edge Therapeutics, Inc., not PDS Biotechnology Corp.
- Review the Phase 3 EG-1962 trial design, enrollment progress, regulatory requirements, and expected timing of the full data readout.
- Assess cash runway against actual clinical-trial spending and the terms, interest costs, covenants, and remaining availability of the amended Hercules facility.
- Confirm payment of the $1.0 million Evonik milestone and monitor additional milestone and royalty obligations.
- Consider dilution exposure from outstanding options and warrants; the filing reported 5.1 million options and 0.6 million common-stock warrants outstanding at June 30, 2016.